title: New insights on SOM230, a universal somatostatin receptor ligand.
authors.affiliation: Novartis Pharma AG, Basel, Switzerland. viktor.boerlin@pharma.novartis.com
authors.forename: V
authors.initials: V
authors.lastname: Boerlin
authors.forename: J
authors.initials: J
authors.lastname: van der Hoek
authors.forename: Ch
authors.initials: Ch
authors.lastname: Beglinger
authors.forename: K W
authors.initials: KW
authors.lastname: Poon
authors.forename: S
authors.initials: S
authors.lastname: Hartmann
authors.forename: C
authors.initials: C
authors.lastname: Dutreix
authors.forename: J M
authors.initials: JM
authors.lastname: Kovarik
authors.forename: Ch
authors.initials: Ch
authors.lastname: Bruns
authors.forename: G
authors.initials: G
authors.lastname: Weckbecker
authors.forename: I
authors.initials: I
authors.lastname: Lewis
authors.forename: P
authors.initials: P
authors.lastname: Schnieper
authors.forename: L J
authors.initials: LJ
authors.lastname: Hofland
authors.forename: S W J
authors.initials: SW
authors.lastname: Lamberts
mesh_terms: D000172:Acromegaly / Q000188:drug therapy* / Q000378:metabolism; D004305:Dose-Response Relationship, Drug; D004341:Drug Evaluation; D004361:Drug Tolerance; D015507:Drugs, Investigational / Q000009:adverse effects / Q000627:therapeutic use*; D019382:Human Growth Hormone / Q000187:drug effects* / Q000378:metabolism; D009325:Nausea / Q000209:etiology; D015282:Octreotide / Q000009:adverse effects / Q000627:therapeutic use; D017481:Receptors, Somatostatin / Q000145:classification / Q000187:drug effects; D012016:Reference Values; D013004:Somatostatin / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D014839:Vomiting / Q000209:etiology
chemical_list: D015507:Drugs, Investigational; D017481:Receptors, Somatostatin; D019382:Human Growth Hormone; D013004:Somatostatin; C517782:pasireotide; D015282:Octreotide